Five Prime Therapeutics Inc
Anti-FGFR2 Antibody Formulations

Last updated:

Abstract:

This disclosure relates to a formulation of an anti-fibroblast growth factor receptor 2 (FGFR2) antibody that, in some embodiments, is capable of being stored as a liquid, for example in a ready-to-use form, and that, in some embodiments, may be administered intravenously such as by intravenous (IV) infusion.

Status:
Application
Type:

Utility

Filling date:

4 Oct 2019

Issue date:

13 Jan 2022